

5. Kobayashi H, Carrasquillo JA, Paik CH, Waldmann TA, Tagaya Y. Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15. *Cancer Res.* 2000; 60(13): 3577–83.
6. ImmunityBio. 14. 2. 2022, ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New 'Magnitude of Benefit' in Patients with BCG Unresponsive Bladder Cancer (online). Dostupné z: <https://immunitybio.com/immunitybio-announces-over-24-months-median-duration-of-complete-remission-with-100%-NBIMC-CIS>.
7. Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. *Frontiers in pharmacology.* 2017; 8: 561.
8. Kumar V, Chaudhary N, Garg M, et al. Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. *Frontiers in pharmacology.* 2017; 8: 311.
9. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science.* 2017; 357(6349): 409–13.
10. Thana M, Wood L. Immune checkpoint inhibitors in genitourinary malignancies. *Current oncology.* 2020; 27(Suppl. 2): S69–S77.
11. Mondal M, Guo J, He P, et al. Recent advances of oncolytic virus in cancer therapy. *Human vaccines & immunotherapeutics.* 2020; 16(10): 2389–402.
12. Razzaghdoust A, Rahmatizadeh S, Mofid B, et al. Data-Driven Discovery of Molecular Targets for Antibody-Drug Conjugates in Cancer Treatment. *BioMed research international.* 2021; 2021: 2670573.
13. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. *Science.* 2015; 348(6230): 62–8.
14. Perera MPJ, Thomas PB, Risbridger GP, et al. Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer. *Cancers.* 2022; 14(3).
15. Madan RA, Antonarakis ES, Drake CG, et al. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. *Journal of the National Cancer Institute.* 2020; 112(6): 562–73.
16. Vogelzang NJ, Beer TM, Gerritsen W, et al. Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. *JAMA oncology.* 2022.
17. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. *The New England journal of medicine.* 2021; 385(12): 1091–103.
18. Schulz GB, Black PC. Combination therapies involving checkpoint-inhibitors for treatment of urothelial carcinoma: a narrative review. *Translational andrology and urology.* 2021; 10(10): 4014–21.
19. Kwon WA, Seo HK. Emerging agents for the treatment of metastatic urothelial cancer. *Investigative and clinical urology.* 2021; 62(3): 243–55.
20. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. *The New England journal of medicine.* 2021; 384(12): 1125–35.
21. Bansal A, Singh J, Kaur S, Kaur N. Enfortumab Vedotin-Induced Toxic Epidermal Necrolysis: A Rare Fatal Adverse Reaction. *Indian dermatology online journal.* 2022; 13(1): 128–30.
22. Schmidinger M, Resch I, Fajkovic H, et al. Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma? *Current opinion in urology.* 2021; 31(3): 270–5.